NK cells are migrated and indispensable in the anti-tumor activity induced by CCL27 gene therapy

Cancer Immunology, Immunotherapy

Volumn 58, Issue 2, 2009, Pages 291-299

  Gao, Jian Qing ^a   Tsuda, Yasuhiro ^b   Han, Min ^a   Xu, Dong Hang ^a   Kanagawa, Naoko ^b   Hatanaka, Yutaka ^c   Tani, Yoichi ^c   Mizuguchi, Hiroyuki ^d   Tsutsumi, Yasuo ^d   Mayumi, Tadanori ^e   Okada, Naoki ^b   Nakagawa, Shinsaku ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b OSAKA UNIVERSITY   (Japan)

^c Dako Japan Co Ltd   (Japan)

^d NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^e KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

Adenovirus vector; Anti tumor; CCL27; Interleukin 12; mCCR10; NK cell; OV HM

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; CCL27 PROTEIN, HUMAN; CUTANEOUS T CELL ATTRACTING CHEMOKINE; INTERLEUKIN 12; OLIGOPEPTIDE; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL MOTION; FEMALE; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; INTRALESIONAL DRUG ADMINISTRATION; MOUSE; NATURAL KILLER CELL; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CCL27; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; INTERLEUKIN-12; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; OVARIAN NEOPLASMS;

EID: 58149392571     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-008-0554-x     Document Type: Article

References (48)

1. Blattman JN, Greenberg PD (2004) Cancer immunotherapy: a treatment for the masses. Science 305:200-205 (Pubitemid 38886725)
2. Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, Terabe M, Belyakov IM (2004) Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 113:1515-1525 (Pubitemid 39071672)
3. Gao JQ, Okada N, Mayumi T, Nakagawa S (2008) Immune cell recruitment and cell-based system for cancer therapy. Pharm Res 25:752-768
4. Stutman O (1974) Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 183:534-536
5. Homey B, Muller A, Zlotnik A (2002) Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2:175-184 (Pubitemid 37328764)
6. Zhang L, Yang N, Conejo-Garcia JR, Katsaros D, Mohamed- Hadley A, Fracchioli S, Schlienger K, Toll A, Levine B, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence and survival in epithelial ovarian cancer. N Engl J Med 348:203-213 (Pubitemid 36077915)
7. Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12:121-127 (Pubitemid 30398626)
8. Rossi D, Zlotnik A (2000) The biology of chemokines and their receptors. Annu Rev Immunol 18:217-42
9. Zlotnik A, Yoshie O, Nomiyama H (2006) The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 7:243
10. Okada N, Gao JQ, Sasaki A, Niwa M, Okada Y, Nakayama T, Yoshie O, Mizuguchi H, Hayakawa T, Fujita T, Yamamoto A, Tsutsumi Y, Mayumi T, Nakagawa S (2004) Anti-tumor activity of chemokine is affected by both the kinds of tumors and the activation state of host's immune system: implications for chemokinebased cancer immunotherapy. Biochem Biophys Res Commun 317:68-76 (Pubitemid 38401966)
11. Slettenaar VI, Wilson JL (2006) The chemokine network: a target in cancer biology? Adv Drug Deliv Rev 58:962-974 (Pubitemid 44780906)
12. Paillard F (1999) Cytokine and chemokine: a stimulating couple. Hum Gene Ther 10:695-696
13. Nomura T, Hasegawa H (2000) Chemokines and anti-cancer immunotherapy: anti-tumor effect of EBI1-ligand chemokine (ELC) and second lymphoid tissue chemokine (SLC). Anticancer Res 20:4073-4080
14. Fushimi T, Kojima A, Moore MA, Crystal RG (2000) Macrophage inflammatory protein 3 alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J Clin Invest 105:1383-1393 (Pubitemid 30322404)
15. Fushimi T, O'Connor TP, Crystal RG (2006) Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth. Cancer Res 66:3513-3522
16. Gao JQ, Sugita T, Kanagawa N, Iida K, Okada N, Mizuguchi H, Nakayama T, Hayakawa T, Yoshie O, Tsutsumi Y, Mayumi T, Nakagawa S (2005) Anti-tumor responses induced by chemokine CCL19 transfected into an ovarian carcinoma model via fibermutant adenovirus vector. Biol Pharm Bull 28:1066-1070 (Pubitemid 40880316)
17. O'Hayre M, Salanga CL, Handel TM, Allen SJ (2008) Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J 409:635-649 (Pubitemid 351214190)
18. Xin H, Kikuchi T, Andarini S, Ohkouchi S, Suzuki T, Nukiwa T, Huqun Hagiwara K, Honjo T, Saijo Y (2005) Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 35:1371-1380 (Pubitemid 40691418)
19. Kolber DL, Knisely TL, Maione TE (1995) Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst 87:304-309
20. Tannenbaum CS, Tubbs R, Amstrong D, Finke JH, Bukowski RM, Hamilton TA (1998) The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 161:927-932 (Pubitemid 28323558)
21. Sgadari C, Farber JM, Angiolillo AL, Liao F, Teruya-Feldstein J, Burd PR, Yao L, Gupta G, Kanegane C, Tosato G (1997) Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 89:2635-2643 (Pubitemid 27172547)
22. Maghazachi AA, AI-Aoukaty A, Schall TJ (1996) CC chemokines induce the generation of killer cells from CD56+ cells. Eur J Immunol 26:315-319
23. Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C (2000) Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 165:1992-2000 (Pubitemid 30643148)
24. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581-586
25. Kerbel RS, Hawley RG (1995) Interlrukin 12: newest member of the antiangiogenesis club. J Natl Cancer Inst 87:557-559
26. Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G (1999) Contribution of natural killer cells to inhibition of angiogenesis by interleukin 12. Blood 93:1612-1621 (Pubitemid 29102489)
27. Gao JQ, Tsuda Y, Katayama K, Nakayama T, Hatanaka Y, Tani Y, Mizuguchi H, Hayakawa T, Yoshie O, Tsutsumi Y, Mayumi T, Nakagawa S (2003) Anti-tumor EVect by interleukin-11 receptor alpha-locus chemokine/CCL27, introduced into tumor cells through a recombinant adenovirus vector. Cancer Res 63:4420-4425 (Pubitemid 36951013)
28. Reiss Y, Proudfoot AE, Power CA, Campbell JJ, Butcher EC (2001) CC chemokine receptor (CCR) 4 and the CCR 10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 194:1541-1547 (Pubitemid 33081528)
29. Morales J, Homey B, Vicari AP, Hudak S, Oldham E, Hedrick J, Orozco R, Copeland NG, Jenkins NA, McEvoy LM, Zlotnik A (1999) CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc Natl Acad Sci USA 96:14470-14475 (Pubitemid 30000674)
30. Mizuguchi H, Koizumi N, Hosono N, Utoguchi N, Watanabe Y, Kay MA, Hayakawa T (2001) A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their Wber knob. Gene Ther 8:730-735 (Pubitemid 32496435)
31. Mizuguchi H, Kay MA (1998) EYcient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 9:2577-2583 (Pubitemid 29004630)
32. Mizuguchi H, Kay MA (1999) A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 10:2013-2017 (Pubitemid 29387915)
33. Faaij CM, Lankester AC, Spierings E, Hoogeboom M, Bowman EP, Bierings M, Revesz T, Egeler RM, van Tol MJ, Annels NE (2006) A possible role for CCL27/CTACK-CCR10 interaction in recruiting CD4 T cells to skin in human graft-versus-host disease. Br J Haematol 133:538-549
34. Mule JJ, Custer M, Averbook B, Yang JC, Weber JS, Goeddel DV, Rosenberg SA, Schall TJ (1996) RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther 7:1545-1553 (Pubitemid 26302209)
35. Guo J, Wang B, Zhang M, Chen T, Yu Y, Regulier E, Homann H, Qin Z, Ju DW (2002) Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther 9:793-803 (Pubitemid 34679307)
36. Laning J, Kawasaki H, Tanaka E, Luo Y, Dorf ME (1994) Inhibition of in vivo tumor growth by the beta chemokine, TCA3. J Immunol 153:4625-4635 (Pubitemid 24346858)
37. Maric M, Chen L, Sherry B, Liu Y (1997) A mechanism for selective recruitment of CD8 T cells into B7-1-transfected plasmacytoma: role of macrophage-inflammatory protein 1 α. J Immunol 159:360-368 (Pubitemid 127493720)
38. Fujiwara H, Hamaoka T (1996) Antitumor and antimetastatic effects of interleukin 12. Cancer Chemother Pharmacol 38:S22-S26
39. Ogawa M, Umehara K, Yu WG, Uekusa Y, Nakajima C, Tsujimura T, Kubo T, Fujiwara H, Hamaoka T (1999) A critical role for a peritumoral stromal reaction in the induction of T-cell migration responsible for interleukin-12-induced tumor regression. Cancer Res 59:1531-1538 (Pubitemid 29160122)
40. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-915 (Pubitemid 39273730)
41. Ramarathinam L, Castle M, Wu Y, Liu Y (1994) T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 179:1205-1214 (Pubitemid 24091779)
42. Emtage PC, Wan Y, Hitt M, Graham FL, Muller WJ, Zlotnik A, Gauldie J (1999) Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther 10:697-709 (Pubitemid 29168155)
43. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil JC, Olague C, Sola J, Sadaba B, Lacasa C, Melero I, Qian C, Prieto J (2004) Phase 1 trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 22:1389-1397 (Pubitemid 41103620)
44. Wadler S, Levy D, Frederickson HL, Falkson CI, Wang Y, Weller E, Burk R, Ho G, Kadish AS, Eastern Cooperative Oncology Group (2004) Phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. Gynecol Oncol 92:957-964 (Pubitemid 38251402)
45. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwarz M, Garbe C (2003) Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 89:1620-1626 (Pubitemid 37464130)
46. Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13:251-276
47. Gao JQ, Kanagawa N, Motomura Y, Yanagawa Y, Sugita T, Hatanaka Y, Tani Y, Mizuguchi H, Tsutsumi Y, Mayumi T, Okada N, Nakagawa S (2007) Cotransduction of CCL27 gene can improve the efficacy and safety of IL-12 gene therapy for cancer. Gene Ther 14:491-502 (Pubitemid 46390922)
48. Narvaiza I, Mazzolini G, Barajas M, Duarte M, Zaratiegui M, Qian C, Melero I, Prieto J (2000) Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-inducible protein- 10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol 164:3112-3122 (Pubitemid 30148972)